| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2001; 40: 1211-1220
© 2001 British Society for Rheumatology
Original Papers |
The therapeutic approach of early intervention for rheumatoid arthritis: what is the evidence?*
Rheumatology and Rehabilitation Research Unit, University of Leeds, Leeds, UK
Objective. The concepts of early intervention and early arthritis clinics for the management of rheumatoid arthritis (RA) were introduced almost a decade ago. The evidence for these is diverse and the best therapeutic approach remains vehemently debated. This review addresses these issues.
Methods. The MEDLINE database was searched to identify relevant papers satisfying inclusion criteria for disease duration and no previous use of disease-modifying anti-rheumatic drugs (DMARDs). Where possible, evidence was obtained from randomized controlled trials. We selected the most relevant topics to best justify early therapeutic intervention in RA.
Results. The benefit of DMARDs over placebo and delayed therapy is unquestionable from the studies presented, with reduction in bone damage and preservation of function. Through prevention of disability, early treatment should be the most cost-effective approach. The evidence presented supports the use of DMARDs when the diagnosis of RA is first made. Delay in treatment may result in irreversible damage. There is insufficient evidence to recommend combination therapy for all patients at disease onset. Further research into newer therapies is required before their routine first-line use is recommended.
Conclusions. Early therapeutic intervention in RA reduces long-term disability and joint damage. Optimal management appears to be the early identification of non-responders and targeted combination therapy. Biological therapies have the potential to revolutionize the treatment of early RA.
KEY WORDS: Early rheumatoid arthritis, Combination therapy, Corticosteroids, DMARDs, Anti-TNF-
agents.
* This review contains elements of the presentation ‘Therapy of early RA: evidence-based approach’ made at the XVI European League Against Rheumatism (EULAR) Congress, Glasgow, UK, 6–11 June 1999.
Correspondence to: P. Emery, University of Leeds, Rheumatology and Rehabilitation Research Unit, 36 Clarendon Road, Leeds LS2 9NZ, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  L. G. Schipper, J. Fransen, P. Barrera, and P. L. C. M. Van Riel Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs Rheumatology, July 1, 2009; 48(7): 828 - 833. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P Emery, R Van Vollenhoven, M Ostergaard, E Choy, B Combe, W Graninger, K Krueger, M Matucci-Cerinic, F Navarro, P van Riel, et al. Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe Ann Rheum Dis, April 1, 2009; 68(4): 456 - 459. [Full Text] [PDF]
|
|
|
|
|
|
I Hafstrom, K Albertsson, A Boonen, D van der Heijde, R Landewe, B Svensson, and for the BARFOT Study Group Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study Ann Rheum Dis, April 1, 2009; 68(4): 508 - 513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Quinn, A. K. S. Gough, M. J. Green, J. Devlin, E. M. A. Hensor, A. Greenstein, A. Fraser, and P. Emery Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome Rheumatology, April 1, 2006; 45(4): 478 - 480. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. S. Choy, C. Smith, C. J. Dore, and D. L. Scott A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal Rheumatology, November 1, 2005; 44(11): 1414 - 1421. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Harle, T. Bongartz, J. Scholmerich, U. Muller-Ladner, and R. H. Straub Predictive and potentially predictive factors in early arthritis: a multidisciplinary approach Rheumatology, April 1, 2005; 44(4): 426 - 433. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. P. K. Nell, K. P. Machold, G. Eberl, T. A. Stamm, M. Uffmann, and J. S. Smolen Benefit of very early referral and very early therapy with disease-modifying anti-rheumatic drugs in patients with early rheumatoid arthritis Rheumatology, July 1, 2004; 43(7): 906 - 914. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kary, J. Fritz, H. U. Scherer, and G. R. Burmester Do we still miss the chance of effectively treating early rheumatoid arthritis? New answers from a new study Rheumatology, July 1, 2004; 43(7): 819 - 820. [Full Text] [PDF]
|
|
|
|
|
|
V. V. Kaushik, V. E. Abernethy, M. P. Lynch, and J. K. Dawson Outcome measures for rheumatologists Rheumatology, July 1, 2003; 42(7): 902 - 903. [Full Text] [PDF]
|
|
|
|
|
|
G. J. Gormley, W. K. Steele, A. Gilliland, P. Leggett, G. D. Wright, A. L. Bell, C. Matthews, G. Meenagh, E. Wylie, R. Mulligan, et al. Can diagnostic triage by general practitioners or rheumatology nurses improve the positive predictive value of referrals to early arthritis clinics? Rheumatology, June 1, 2003; 42(6): 763 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Potter, D. Mulherin, M. Pugh, P. Emery, M. Quinn, and P. Conaghan Early intervention with disease-modifying therapy for rheumatoid arthritis: where do the delays occur? Rheumatology, August 1, 2002; 41(8): 953 - 955. [Full Text] [PDF]
|
|
|
|
|
|
M H Weisman Newly diagnosed rheumatoid arthritis Ann Rheum Dis, April 1, 2002; 61(4): 287 - 289. [Full Text] [PDF]
|
|